CR8426A - ANTI-IGF-I RECEIVER ANTIBODY - Google Patents

ANTI-IGF-I RECEIVER ANTIBODY

Info

Publication number
CR8426A
CR8426A CR8426A CR8426A CR8426A CR 8426 A CR8426 A CR 8426A CR 8426 A CR8426 A CR 8426A CR 8426 A CR8426 A CR 8426A CR 8426 A CR8426 A CR 8426A
Authority
CR
Costa Rica
Prior art keywords
antibodies
igf
cancer
receptor
elevated levels
Prior art date
Application number
CR8426A
Other languages
Spanish (es)
Inventor
Singh Rajeeva
J Tavares Daniel
E Dagdigian Nancy
Original Assignee
Immunogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/729,441 external-priority patent/US8034904B2/en
Application filed by Immunogen Inc filed Critical Immunogen Inc
Publication of CR8426A publication Critical patent/CR8426A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)

Abstract

Los anticuerpos, anticuerpos humanizados, anticuerpos recubiertos, fragmentos de anticuerpo, anticuerpos derivatizados y conjugados de los mismos con agentes citotoxicos, que especificamente se enlazan a, e inhiben al receptor del factor I de crecimiento de tipo insulina, antagonizan los efectos de IGF-l, IGF-lI y suero en el crecimiento y supervivencia de celulas de tumor, y que substancialmente carecen de actividad agonista. Los anticuerpos y fragmentos de los mismos por consiguiente se pueden utilizar, opcionalmente en conjuncion con otros agente terapeuticos, en el tratamiento de tumores que expresan niveles elevados del receptor IGF-l, tales como cancer de pecho, cancer de colon, cancer de pulmon, sarcoma sinovial, cancer de prostata, y cancer pancreatico, y los anticuerpos derivatizados se pueden utilizar en el diagnostico y formacion de imagenes de tumores que expresan niveles elevados del IGF-I.Antibodies, humanized antibodies, coated antibodies, antibody fragments, derivatized antibodies and conjugated thereof with cytotoxic agents, which specifically bind to, and inhibit the insulin-like growth factor I receptor, antagonize the effects of IGF-1. , IGF-lI and serum in the growth and survival of tumor cells, and which substantially lack agonist activity. The antibodies and fragments thereof can therefore be used, optionally in conjunction with other therapeutic agents, in the treatment of tumors expressing elevated levels of the IGF-1 receptor, such as breast cancer, colon cancer, lung cancer, Synovial sarcoma, prostate cancer, and pancreatic cancer, and derivatized antibodies can be used in the diagnosis and imaging of tumors that express elevated levels of IGF-I.

CR8426A 2003-12-08 2006-06-01 ANTI-IGF-I RECEIVER ANTIBODY CR8426A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/729,441 US8034904B2 (en) 2002-06-14 2003-12-08 Anti-IGF-I receptor antibody

Publications (1)

Publication Number Publication Date
CR8426A true CR8426A (en) 2007-12-04

Family

ID=36616549

Family Applications (1)

Application Number Title Priority Date Filing Date
CR8426A CR8426A (en) 2003-12-08 2006-06-01 ANTI-IGF-I RECEIVER ANTIBODY

Country Status (13)

Country Link
EP (1) EP1692176A4 (en)
JP (1) JP2008502589A (en)
KR (1) KR20070001883A (en)
CN (1) CN1886424A (en)
AU (1) AU2004303792A1 (en)
BR (1) BRPI0417406A (en)
CA (1) CA2548065A1 (en)
CR (1) CR8426A (en)
EA (1) EA009807B1 (en)
EC (1) ECSP066595A (en)
IL (1) IL174770A0 (en)
MX (1) MXPA06005540A (en)
NO (1) NO20063155L (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107095846A (en) 2009-12-21 2017-08-29 霍夫曼-拉罗奇有限公司 Antibody formulations
CA2800311A1 (en) * 2010-05-11 2011-11-17 Aveo Pharmaceuticals, Inc. Anti-fgfr2 antibodies
US9051561B2 (en) 2011-10-10 2015-06-09 Children's Hospital Los Angeles Asparaginase and treating diseases associated with asparagine dependence
CN103509117B (en) * 2013-05-06 2016-03-09 江苏匡亚生物医药科技有限公司 Bi-specific antibody of anti-human HER2 and people IGF-IR and its production and use
CA3056573A1 (en) * 2017-05-30 2018-12-06 Teijin Pharma Limited Anti-igf-i receptor antibody
EP4678186A1 (en) * 2023-03-07 2026-01-14 Akeso Pharma Co., Ltd. Pharmaceutical composition comprising anti-ctla4-anti-pd-1 bispecific antibody and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL143514A0 (en) * 1998-12-04 2002-04-21 Novartis Ag METHODS AND COMPOSITIONS USEFUL FOR TARGETING ACTIVATED VITRONECTIN RECEPTOR αvβ3
NZ527302A (en) * 2001-01-05 2006-10-27 Abgenix Inc Antibodies to insulin-like growth factor I receptor
US7538195B2 (en) * 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
KR20050109489A (en) * 2003-02-13 2005-11-21 화이자 프로덕츠 인크. Uses of anti-insulin-like growth factor ⅰ receptor antibodies

Also Published As

Publication number Publication date
JP2008502589A (en) 2008-01-31
EP1692176A4 (en) 2008-11-12
AU2004303792A1 (en) 2005-07-07
EA200600931A1 (en) 2006-10-27
EP1692176A1 (en) 2006-08-23
ECSP066595A (en) 2006-10-17
NO20063155L (en) 2006-08-11
IL174770A0 (en) 2006-08-20
KR20070001883A (en) 2007-01-04
EA009807B1 (en) 2008-04-28
MXPA06005540A (en) 2006-08-17
CA2548065A1 (en) 2005-07-07
BRPI0417406A (en) 2007-04-03
CN1886424A (en) 2006-12-27

Similar Documents

Publication Publication Date Title
AR061911A1 (en) ANTAGONIST ANTIBODY FOR THE TREATMENT OF CANCER
ATE507244T1 (en) ANTI-IGF-I RECEPTOR ANTIBODIES
ES2571235T3 (en) Procedure for the treatment of a blood tumor that uses the anti-TIM-3 antibody
UA94388C2 (en) Anti-integrin immunoconjugate and treatment method using thereof
AR070862A1 (en) COMBINATION THERAPY WITH C-MET AND HER ANTAGONISTS
CL2017001580A1 (en) Antibody or antibody fragment against humanized antibody cd38, conjugated to the antibody with a cytotoxic compound pharmaceutical composition with said antibodies using antibodies to treat cancer or autoimmune disease method to diagnose cancer polynucleotide vector and host cell.
AR061245A1 (en) COMPOSITIONS AND METHODS FOR VASCULAR DEVELOPMENT MODULATION
GT200600324A (en) NEW ANTI-IGF-IR ANTIBODIES AND USES OF THE SAME
UA99608C2 (en) PDGFRb-SPECIFIC INHIBITORS
CL2008003846A1 (en) Use of compounds derived from 1,2,4-triazolo fused with heterocycles, which act as ligands of the androgen receptor (ar); compounds; Preparation process; Pharmaceutical composition and the use of said compounds for the treatment of prostate cancer.
PT2326665E (en) Non-cytotoxic fusion proteins comprising egf muteins
WO2006099141A3 (en) Anti-mesothelin antibodies
NO20070945L (en) Induction of apoptosis in tumor cells expressing Toll-like receptor
EA032908B1 (en) ANTIBODY MEDICINE (ADC) CONJUGATES THAT CONTACT PROTEINS 158P1D7
AR077241A1 (en) METHOD OF TREATMENT OF CANCER CONANTAGONIST DLL4 AND CHEMOTHERAPEUTIC AGENT
WO2011137245A3 (en) Lytic-peptide-her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use
ECSP066595A (en) ANTI-IGF-I RECEIVER ANTIBODY
PE20130460A1 (en) COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMORS
EP1909783A4 (en) LIQUID ANALOGUES USEFUL AS ANTICANCER AGENTS
Shi et al. Antibody-drug conjugates in breast cancer: advances and prospects
EA200601405A1 (en) HUMANIZED ANTIBODY
ZA202407179B (en) Novel mcl-1 inhibitor and combination of mcl-1 and a bh3 mimetic, such as a bcl-2 inhibitor
JP2018516230A5 (en)
MD2849G2 (en) Method of mammary cancer treatment to patients of old age
DOP2009000003A (en) ANTAGONIST ANTIBODY FOR THE TREATMENT OF CANCER

Legal Events

Date Code Title Description
FC Refusal